(Q46127987)

English

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

scientific article published in November 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

14

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

author name string

José Carlos Paradiñeiro

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Silvia Sauleda

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Elena García-Arumí

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Eva Castella

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Carolina Puiggròs

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Manuel Crespo

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Maria Feijoo

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Marjorie Diaz

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Sara Villar Del Saz

11

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Merçè Planas

12

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Delia Sureda

13

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Imma Ocaña

15

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Albert Pahissa

16

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

publication date

1 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

407-417

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Antiretroviral-therapy-associated lipoatrophy: current status and future directions

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Stavudine: an update of its use in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Redefining lipodystrophy syndrome: risks and impact on clinical decision making

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Bioelectrical impedance analysis-part II: utilization in clinical practice.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-407

21 January 2018

Identifiers

10.1310/HCT0906-407

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19203906

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46127987&oldid=1587030480"